- Home
- TCRX vs IAE Comparison
TCRX vs IAE Comparison
Compare TCRX & IAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- IAE
- Stock Information
- Founded
- TCRX 2018
- IAE 2007
- Country
- TCRX United States
- IAE United States
- Employees
- TCRX N/A
- IAE N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- IAE Trusts Except Educational Religious and Charitable
- Sector
- TCRX Health Care
- IAE Finance
- Exchange
- TCRX Nasdaq
- IAE Nasdaq
- Market Cap
- TCRX 91.7M
- IAE 74.3M
- IPO Year
- TCRX 2021
- IAE N/A
- Fundamental
- Price
- TCRX $1.60
- IAE $7.32
- Analyst Decision
- TCRX Strong Buy
- IAE
- Analyst Count
- TCRX 5
- IAE 0
- Target Price
- TCRX $9.40
- IAE N/A
- AVG Volume (30 Days)
- TCRX 219.1K
- IAE 46.3K
- Earning Date
- TCRX 11-11-2025
- IAE 01-01-0001
- Dividend Yield
- TCRX N/A
- IAE 10.21%
- EPS Growth
- TCRX N/A
- IAE N/A
- EPS
- TCRX N/A
- IAE N/A
- Revenue
- TCRX $6,961,000.00
- IAE N/A
- Revenue This Year
- TCRX $255.18
- IAE N/A
- Revenue Next Year
- TCRX N/A
- IAE N/A
- P/E Ratio
- TCRX N/A
- IAE N/A
- Revenue Growth
- TCRX N/A
- IAE N/A
- 52 Week Low
- TCRX $1.02
- IAE $5.31
- 52 Week High
- TCRX $6.23
- IAE $6.45
- Technical
- Relative Strength Index (RSI)
- TCRX 36.40
- IAE 64.46
- Support Level
- TCRX $1.73
- IAE $7.22
- Resistance Level
- TCRX $1.96
- IAE $7.25
- Average True Range (ATR)
- TCRX 0.11
- IAE 0.07
- MACD
- TCRX -0.03
- IAE 0.01
- Stochastic Oscillator
- TCRX 0.00
- IAE 91.60
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About IAE Voya Asia Pacific High Dividend Equity Income Fund ING Asia Pacific High Dividend Equity Income Fund of Beneficial Interest
Voya Asia Pacific High Dividend Equity Income Fund is a United States-based diversified, closed-end fund.The investment objective of the fund is to provide a total return through a combination of current income, capital gains, and capital appreciation. To achieve this objective, under normal market conditions, the fund invests in a portfolio of dividend-yielding equity securities of companies located in the Asia Pacific region.